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Abstract
Background and Objective
Matrix metalloproteinase (MMP) -8, -9 and myeloperoxidase (MPO) are inflammatory medi-
ators. The potential associations between MMP-8, -9, MPO and their abilities to reflect car-
diovascular risk remains to be evaluated in saliva. The objective of this study was to
investigate the levels and associations of salivary MMP-8, -9, MPO and tissue inhibitors of
metalloproteinase (TIMP)-1 in myocardial infarction (MI) patients and controls with or with-
out periodontitis.
Materials and Methods
200 patients with a first MI admitted to coronary care units in Sweden from May 2010 to
December 2011 and 200 controls matched for age, gender, residential area and without
previous MI were included. Dental examination and saliva sample collection was performed
6-10 weeks after the MI in patients and at baseline in controls. The biomarkers MMP -8, -9,
MPO and TIMP-1 were analyzed by time-resolved immunofluorescence assay (IFMA),
Western blot and Enzyme-Linked ImmunoSorbent Assay (ELISA).
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Results
After compensation for gingivitis, gingival pockets and smoking, the mean salivary levels of
MMP-8 (543 vs 440 ng/mL, p = 0.003) and MPO (1899 vs 1637 ng/mL, p = 0.02) were higher
in non-MI subjects compared to MI patients. MMP-8, -9 and MPO correlated positively with
clinical signs of gingival/periodontal inflammation while TIMP-1 correlated mainly negatively
with these signs. The levels of latent and active forms of MMP-8 did not differ between the
MI and non-MI groups. Additionally, MMP-8, MPO levels and MMP-8/TIMP-1 ratio were sig-
nificantly higher in men compared to women with MI.
Conclusions
This study shows that salivary levels of the analyzed biomarkers are associated with peri-
odontal status. However, these biomarkers could not differentiate between patients with or
without a MI. These findings illustrate the importance to consider the influence of oral condi-
tions when analyzing levels of inflammatory salivary biomarkers.
Introduction
Periodontal disease is an inflammatory condition appearing commonly in the adult population
[1]. The prevalence of periodontal diseases varies, from gingivitis (prevalence 90%) to moder-
ate (35%) and severe (5–8%) periodontitis [2]. An association between periodontitis and car-
diovascular disease (CVD) is known but the pathological mechanisms and potential links
between the two diseases are not yet completely clarified [3].
Matrix metalloproteinases (MMP) are calcium- dependent zinc containing endopeptidases
that play an important role in normal physiological processes such as tissue development and
remodeling as well as in pathological processes [4]. Twenty-three genetically distinct MMPs
have been identified in humans. They have an anti-inflammatory (defensive) as well as a patho-
genic (tissue destructive) role and are involved in the pathogenesis of large number of different
diseases and conditions [5]. MMPs are produced in latent, non-active pro-forms and activated
extra- or intracellularly depending upon the structure of the MMP molecule [6]. The main
inhibitors of MMPs are tissue inhibitors of metalloproteinases (TIMPs) that restrict extracellu-
lar matrix component breakdown [7].
MMP-8, also known as collagenase-2 or neutrophil collagenase, is related to inflammatory
conditions. It is expressed mainly by neutrophils [8] but also by endothelial and smooth muscle
cells and macrophages in atherosclerotic lesions [9, 10]. Apoptosis of endothelial cells and
release of MMP-8 promote the conversion of stable lesions to unstable lesions and lead to pla-
que rupture [11] and elevated MMP-8 levels have been found in rupture prone and vulnerable
plaques [10]. Furthermore, salivary MMP-8 levels are associated with progressive loss of
attachment in periodontitis [8, 12]. MMP-9 (gelatinase B) is increased in stimulated whole
saliva from inflamed periodontal sites [13, 14]. Increased levels of MMP-9 in serum have also
been shown to be a marker of cardiovascular disease [15].
Myeloperoxidase (MPO) is strongly associated with on-going inflammation [16] but has
widely been used as a marker of both acute and chronic inflammatory conditions. Its main role
is to generate hypochlorous acid to kill bacteria. The oxidative function of MPO also activates
latent forms of proMMP-8 and -9 and inactivates TIMPs [17, 18]. MPO is associated with CVD
and elevated salivary MPO levels have been demonstrated in periodontal disease [19–22].
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The objective of the current study was to investigate salivary MMP-8, -9, TIMP-1 and MPO
levels in relation to MI and periodontal disease.
Materials and Methods
Ethics Statement
The case-control PAROKRANK study (Periodontal disease and the relation to myocardial
infarction), including the study protocols for participant recruitment, and informed consent
for participants, were approved by the regional ethical review board (Dnr. 2008/152-31/2) Kar-
olinska Institutet, Stockholm, Sweden. All participants gave their written informed consent.
Study population
Two-hundred patients,< 75 years old and admitted to a coronary care unit with a first MI
were enrolled. Enrollment for this sub-study occurred between May 2010 and December 2011
at eleven participating hospitals in Sweden. The MI was diagnosed according to international
definitions [23, 24]. In addition, 200 control subjects with no history of MI and matched for
age, gender and postal code were recruited from the national population registry. Study partici-
pants were excluded if they had undergone cardiac valvular surgery or had language barriers
preventing them to complete study procedures.
Study protocol
Study participants attended the local cardiology and dental departments for clinical and labora-
tory measurements, questionnaire evaluation and for extensive periodontal examination
including salivary collection. Patients were examined 6–10 weeks after the MI and the matched
controls in close proximity thereafter.
Dental examination and evaluation. All participants fasted one hour prior to the dental
examination. Saliva and bacterial samples were collected first and the subsequent dental exami-
nation comprised number of present teeth, soft tissue pathologies, dental caries and periodon-
tal status, including probing pocket depth (PPD) at four sites per tooth, bleeding on probing
(BOP) and present or absent plaque score. Mobility and furcation involvement were also
recorded.
Collection and preparation of salivary samples. Sample collection: Stimulated saliva
samples were obtained by chewing paraffin wax up to 10 minutes. The produced saliva was col-
lected into a graded test-tube. The saliva collection continued until 2 mL of saliva was obtained
or until 10 minutes had passed. The collected amount was determined, excluding the foam.
Collected samples were immediately frozen at -20°C or lower until processing. Each vial was
thawed and centrifuged at 500g for 5 minutes, at 5°C. The supernatants were aliquoted into 1.5
mL Eppendorf tubes (Eppendorf, Hauppauge, NY, USA), and stored at -80°C. Each saliva ali-
quot was used twice for the determination of selected biomarkers.
Determination of biomarker levels in saliva
The MMP-8 concentrations were determined by an immunofluorescence assay (IFMA). The
monoclonal MMP-8 specific antibodies 8708 and 8706 (Medix Biochemica, Kauniainen, Fin-
land) were used as a catching antibody and a tracer antibody, respectively. The tracer antibody
was labeled using europium-chelate [25]. The assay buffer contained 20 mM Tris-HCl, pH 7.5,
0.5 M NaCl, 5 mM CaCl2, 50 μMZnCl2, 0.5% BSA, 0.05% sodium azide and 20 mg/L diethyle-
netriaminepentaacetic acid (DTPA). Samples were diluted in assay buffer and incubated for
one hour, followed by incubation for one hour with tracer antibody. Enhancement solution was
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added and after 5 min fluorescence was measured using a 1234 Delfia Research Fluorometer
(Wallac, Turku, Finland). The specificity of the monoclonal antibodies against MMP-8 corre-
sponded to that of polyclonal MMP-8. The interassay coefficient of variation (CV) % was 7.3%.
The detection limit for the assay is 0.08 ng/mL. Salivary MMP-9, TIMP-1 and MPO levels were
determined using ELISA kits according to the manufacturer’s instructions (R&D Systems, Min-
neapolis, MN, USA; Amersham Biosciences, Buckinghamshire, UK; Immundiagnostik, Ben-
sheim, Germany, respectlively) [26]. Furthermore, salivary samples were examined byWestern
blotting using polyclonal antibodies against MMP-8. The immunoblot was quantitated by den-
sitometric computer scanning, and the data expressed as arbitrary units [27].
Statistical analysis
Statistical analyses were performed using Statistical Package for Social Sciences (SPSS) version
22 (SPSS Inc., Chicago, IL). Differences were considered significant at a probability level of
p< 0.05. To compare the ratio of categorical variables Chi-squared test was used. The amounts
of the analyzed biomarkers are expressed as median and interquartile range and the signifi-
cance of the differences calculated with Mann-Whitney U test. However, to allow compensa-
tion for smoking, gender and periodontal pockets, when comparing biomarker levels in
patients with and without MI, a General Linear Model test was performed and the values are
expressed as mean ± SD. The resulting p-values were verified with a logarithmic transforma-
tion of the data. Correlations were calculated by using Spearman´s correlation tests.
Results
The results are based on examination of patients 6–10 weeks after the MI and the matched con-
trols at baseline. The mean age was 61±8 in both groups and 84% were male. Tobacco use or
incidence of hypertension and diabetes did not differ between the study groups. Only the total
pathogenic periodontal pocket depth differed between the groups, median 48 mm in the MI
group compared to 38 mm in the non-MI group (p< 0.01) (Table 1).
The mean salivary levels of MMP-8 and MPO were significantly higher in non-MI subjects
after adjustment for smoking, BOP, PPD 4–5 mm and 6 mm (MMP-8; 543 vs 440 ng/mL,
p = 0.003) and MPO; 1899 vs 1637 ng/mL, p = 0.02), (Table 2). In addition, the different
enzyme forms (pro- and active) of MMP-8 obtained as densitometric units from scanning
Western blot images did not differ between MI and non-MI patients. Active MMP-8 levels
were higher in the non-MI group but it didn’t reach the significant level (7.12 (16.6) vs 9.12
(18.1), p = 0.06) (Table 3).
The correlations of salivary MMP-8, -9, MPO, TIMP-1 are shown in Table 4. Most of the
analyzed biomarkers correlated significantly with the other biomarkers. TIMP-1 showed a neg-
ative correlation with MMP-8, -9 and MPO levels.
A weak but significant positive correlation between most of the analyzed biomarkers and
the included clinical variables was seen in both study groups (Table 5). There was a negative
correlation between TIMP-1 and clinical variables.
The association between biomarkers and gender showed that MMP-8, MPO and MMP-8/
TIMP-1 ratio were significantly higher in men with MI. MMP-8 levels in men without MI were
also significantly higher compared to women without MI. There were no differences between
smoker and non-smokers (Table 6).
Discussion
We analyzed salivary levels of MMP-8 and -9, MPO, and TIMP-1 in MI and non-MI subjects
with regard to their periodontal conditions. Salivary levels of MMP-8 were slightly higher in
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the non-MI group. This result differs to some extent, from earlier studies. Furuholm et al. [28]
showed that patients referred for open heart surgery had significantly higher salivary concen-
trations of MMP-8 compared to matched controls after adjusting for number of teeth. No
information about the reason for the open heart surgery or medical treatment was available. A
more recent study showed a lower concentration of MMP-8 in saliva collected 3–4 days after
Table 2. The mean levels of MMP-8, -9, MPO, TIMP-1 and the ratios of MMP-8 and -9/TIMP-1 in stimulated saliva fromMI and non-MI subjects.
Condition/Biomarker MI (n = 200) non-MI (n = 200)
Mean ± SD Mean ± SD p1 p2
MMP-8 (ng/mL) 440 ± 377 543 ± 398 0.008 0.003
MMP-9 (ng/mL) 260 ± 257 264 ± 217 0.88 0.78
MPO (ng/mL) 1637 ± 1386 1899 ± 1447 0.06 0.02
TIMP-1 (ng/mL) 208 ± 119 229 ± 129 0.08 0.09
MMP-8/ TIMP-1 1.63 ± 2.79 1.62 ± 2.48 0.99 0.60
MMP-9/ TIMP-1 0.74 ± 1.45 0.56 ± 0.81 0.12 0.20
p1 indicates signiﬁcance of the differences after a bivariate comparison. p2 indicates the signiﬁcance after compensation for differences in smoking, BOP,
PPD 4–5 mm and PPD  6 mm.
doi:10.1371/journal.pone.0126370.t002
Table 1. Characteristics of the study population.
Condition/Variable MI (n = 200) non-MI (n = 200) p
Male gender; n (%) 168 (84) 168 (84) 1.00
Age (Mean ± SD) 61±8 61±8 0.73
Smoking; n (%)
Yes 19 (10) 26 (13) 0.34
No 74 (38) 83 (42)
Ex-smoker 103 (52) 91 (45)
Snufﬁng; n (%)
Yes 10 (5) 24 (12) 0.07
No 158 (81) 152 (76)
Ex-snuffer 25 (13) 23 (12)
Hypertension; n (%) 83 (42) 67 (34) 0.20
Diabetes; n (%) 18 (9) 10 (5) 0.28
Medical treatment; n (%)
ACEI 136 (68) 21 (11) 0.001
Aspirin 194 (97) 26 (13) 0.001
Beta blocker 180 (90) 31 (16) 0.001
Statins 188 (94) 37 (19) 0.001
Anti-inﬂammatory drugs 4 (2) 10 (5) 0.10
Clinical periodontal status: Median (IQR)
Plaque 53 (50) 45 (47) 0.34
BOP 26 (39) 21 (34) 0.08
PPD 4–5 mm 11 (18) 9 (17) 0.12
PPD  6 mm 0 (2) 1 (0) 0.08
Total PPD mm 48 (88) 38 (71) 0.01
ACEI = angiotensin-converting enzyme inhibitors, IQR = Interquartile range, BOP = bleeding on probing, PPD = probing pocket depth. Signiﬁcance of the
differences calculated with Students t-test (age), Chi 2 or Mann-Whitney´s U test.
doi:10.1371/journal.pone.0126370.t001
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the MI [27] compared to controls, which is in line with our findings. However, the same study
also showed that the percentage of active MMP-8 was higher in the MI group. This differed
from our study where a tendency of more active MMP-8 in the non-MI group was seen,
although the same techniques and anti MMP-8 antibody were used as in Buduneli and co-
authors study [27].
The reason for the discrepancy between the findings in our study and previous studies is not
clear but possible explanations could be the time between the MI and saliva sampling, and the
medication taken by the MI patients. The patients in this investigation were taking a number
different medications, such as statins, angiotensin-converting enzyme inhibitors (ACEI), beta
blockers, anti-inflammatory drugs and thrombocyte inhibitory agents (ASA) that could exert
an effect on salivary levels of MMP-8 and -9, MPO and TIMP-1. According to previous studies
ACEI and statins could potentially interfere with the expression of MPO, MMP-8 and -9. It has
Table 3. Median and interquartile range (IQR) of pro- and active forms of MMP-8 betweenMI patients
and non-MI subjects.
Condition/Enzyme form MI Non-MI
Median (IQR) Median (IQR) p
Pro MMP-8 (au) 7.63 (6.6) 8.19 (6.3) 0.86
Active MMP-8 (au) 7.12 (16.6) 9.12 (18.1) 0.06
au = arbitrary unit.
doi:10.1371/journal.pone.0126370.t003
Table 4. Correlations (r) of salivary MMP-8, -9, MPO, TIMP-1.
Biomarkers MI (n = 200) Non-MI (n = 200)
MMP–8 MPO TIMP–1 MMP–8 MPO TIMP–1
MMP-9 0.5** 0.4** -0.3** 0.3** 0.2** -0.1
MMP-8 0.7** -0.2** 0.7** -0.1
MPO -0.1 -0.1
** Correlation is signiﬁcant at the 0.01 level.
doi:10.1371/journal.pone.0126370.t004
Table 5. Correlations (r) of salivary MMP-8, -9, MPO, TIMP-1 and the ratios of MMP-8 and -9/TIMP-1 measurements and periodontal parameters in
MI (n = 200) and non-MI (n = 200) subjects.
Clinical variable/ Biomarker Plaque BOP PPD 4–5 mm PPD  6mm Total PPD mm
MI non-MI MI non-MI MI non-MI MI non-MI MI non-MI
MMP-8 0.13 0.24** 0.30** 0.37** 0.14 0.17* 0.20** 0.17* 0.01 0.09
MMP-9 0.03 0.07 0.25** 0.08 0.22** 0.01 0.29** 0.02 0.18* -0.05
MPO 0.07 0.22** 0.30** 0.36** 0.16* 0.22* 0.16* 0.19** 0.05 0.16*
TIMP-1 -0.18* -0.38** -0.16* -0.22** -0.10 -0.01 -0.14 -0.10 -0.08 -0.01
MMP-8/ TIMP-1 0.19** 0.39** 0.34** 0.43** 0.17* 0.13* 0.23** 0.15* 0.06 0.05
MMP-9/ TIMP-1 0.11 0.27** 0.27** 0.20** 0.22** -0.04 0.29** 0.05 0.18* -0.08
BOP = bleeding on probing, PPD = probing pocket depth,
* Correlation is signiﬁcant at the 0.05 level;
** Correlation is signiﬁcant at the 0.01 level
doi:10.1371/journal.pone.0126370.t005
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been described that ACE inhibitors can decrease MMP-9 levels in both acute and chronic
phases of systemic conditions while mechanisms of statin use include inhibition of MMP-9 lev-
els [29–31].
The present study did not only correlate salivary biomarkers to MI but also to the periodon-
tal status. The clinical signs of periodontal inflammation, i.e. gingival inflammation (BOP) and
PPD were more or less the same between the study groups. Three of the measured biomarkers,
MMP-8, MMP-9 and MPO correlated with BOP, PPD and clinical periodontal diagnosis.
TIMP-1 generally showed a negative correlation with the clinical signs of oral inflammation.
These results are in agreement with resent studies [32, 33].
Yamamoto et al. showed that MMP-9 plays an important role in the onset and prognosis of
MI [34]. In another study several inflammatory mediators and the relation to severity of CVD
were studied in serum collected from patients with aortic sclerosis. Elevated general MMP
expression was detected and MMP-9 and TIMP-1 had a positive correlation with each other
[35]. In our current study MMP-9 correlated positively with MMP-8 and MPO but had a nega-
tive correlation with TIMP-1 levels. In previous animal studies, TIMP-1 was shown to inhibit
both the activity of MMP-9 during infarct healing and in the protection against infarct plaque
rupture after MI [36].
MPO in plasma is associated with an increased risk of CVD [37]. To our knowledge there
are no studies of MPO in saliva in relation to MI but one cross-sectional study relating salivary
MPO to ischemic stroke has been presented [33]. According to previous reports, MPO exerts
distinct protective and surrogate roles during inflammation, such as inactivation of the patho-
genic microbes and could oxidatively activate latent proMMP-8 and -9 and inactivate TIMPs
[22, 38]. In fact non-proteolytic oxidative activation of proMMP-8 could be directly induced
by MPO-derived hypochlorous acid, which is likely to represent the most direct mechanism
for triggered neutrophils to endogenously activate MMP-8 [38]. Our results showed that MPO
strongly correlated with MMP-8.
MMP-8 is currently regarded among the key biomarkers of inflammation [8, 39]. According
to previous studies, salivary MMP-8 levels are higher in coronary artery disease patients and
Table 6. Biomarkers related to smoking and gender of MI patients and non-MI subjects.
Biomarker MI (n = 200) non MI (n = 200)
Smoking Gender Smoking Gender
Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Current
smokers
Non-
smokers
p Women Men p Current
smokers
Non-
smokers
p Women Men p
MMP-8 350 (587) 275 (536) 0.23 182 (255) 388
(579)
0.01 463 (602) 478 (739) 0.62 335 (598) 487
(633)
0.02
MMP-9 233 (235) 151 (247) 0.09 144 (256) 189
(246)
0.31 240 (277) 225 (260) 0.33 203 (325) 245
(257)
0.19
MPO 1372 (1747) 1077
(1168)
0.16 693
(1102)
1340
(1587)
0.01 1526 (1433) 1454
(1623)
0.99 1181
(1759)
1535
(1593)
0.07
TIMP-1 191 (127) 171 (114) 0.15 180 (130) 187
(125)
0.39 215 (174) 197 (150) 0.31 198 (173) 210
(171)
0.89
MMP-8/
TIMP-1
0.84 (1.78) 0.71 (1.79) 0.59 0.33
(0.76)
0.87
(1.80)
0.01 0.91 (1.59) 0.93 (1.80) 0.70 0.70
(1.33)
0.98
(1.62)
0.08
MMP-9/
TIMP-1
0.28 (0.65) 0.21 (0.69) 0.29 0.16
(0.74)
0.27
(0.60)
0.21 0.29 (0.54) 0.34 (0.66) 0.22 0.29
(0.74)
0.32
(0.53)
0.42
Signiﬁcance of the differences calculated with Mann-Whitney´s U test.
doi:10.1371/journal.pone.0126370.t006
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periodontitis patients [39, 40]. Furuholm and co-authors suggested that increased salivary lev-
els of MMP-8 could reflect periodontal disease activity in patients with coronary artery disease
compared to systemically healthy controls [28]. It has also been suggested that it may reflect
cardiovascular disease, such as MI [28, 41].
It has been demonstrated that GCF levels of MPO and MMP-8 and associations between
them were related to development and treatment responses in patients with chronic peri-
odontitis. This indicates an interaction between the MPO oxidative pathway and MMP-8
activation and this cascade might be useful as a potential biomarker for assessing treatment
outcomes [38].
The strong correlation between the measured salivary biomarkers and clinical conditions in
the mouth illustrates the importance of considering oral inflammation when analyzing salivary
biomarkers for systemic diseases. However, in the present study, MMP-8 and MPO were
higher in the non-MI group also after compensation for periodontal inflammation and smok-
ing, which might be explained, as previously discussed, by the extensive use of medication in
the MI group at time of sample collection, 6–10 weeks after the MI.
In the current investigation, the analyzed biomarkers showed no relation with smoking.
Smoking has been reported to increase as well as decrease levels of inflammatory mediators in
oral fluids [16, 42]. The impact of smoking on salivary biomarkers of acute inflammation may
be explained by a direct effect on inflammatory cells, both on their presence and activity and
also the GCF volume per se. Smoking affect the expression and degranulation of MMPs and
TIMP-1 [42, 43].
Strengths and limitations of this study
Our finding regarding measured salivary enzymes (MMP-8, -9 and MPO), inhibitor (TIMP-1)
and their molar ratios shows statistically significant associations between each other and to MI,
as well as correlation to periodontal status. Salivary samples from patients were collected 6–10
weeks following the MI and the acute inflammatory response evoked by the MI had receded at
this time. In addition, most patients were treated with CVD drugs at this time and this will
likely have affected the analyzed biomarkers compared to if analysis had been performed at
time of the MI.
Conclusion
This study shows that salivary levels of the analyzed biomarkers are associated with periodontal
status. However, these biomarkers could not differentiate between patients with or without a
MI. These findings illustrate the importance to consider the influence of oral conditions when
analyzing levels of inflammatory salivary biomarkers.
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